Clinical trial
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus…
NCT00365365 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00365365 |
|---|---|
| Title | Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer |
| Official title | A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab ± Trastuzumab for the Adjuvant Treatment of Patients With Node-Positive & High-Risk Node-Negative Breast Cancer |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy |
| Enrollment | 214 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Aug 17, 2006 |
| Last update posted | Sep 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: